Health · Pharma & Biotech · 4 hrs ago
Arrowhead's injected RNA drug lowered tau in an early study
Arrowhead Pharmaceuticals tested an injected genetic medicine in an early study.
The medicine was given as a subcutaneous injection, which is delivered under the skin.
The company said it appeared to reach the brain and lower tau levels.
Tau is a protein linked to Alzheimer's disease.
The finding suggests the medicine may affect a brain-related target after an injection under the skin.
The information provided does not say what further studies or next steps are planned.
Arrowhead Pharmaceuticals reported that its genetic medicine lowered levels of tau in an early study.
The medicine was given as a subcutaneous injection.
The company said the drug appeared to travel into the brain.
Tau is described as an Alzheimer’s protein.
- Who
- Arrowhead Pharmaceuticals.
- What
- Its genetic medicine appeared to travel into the brain and lower tau levels in an early study.
- When
- The article was published on 2026-10-14; the study date is not stated.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Company
- Arrowhead Pharmaceuticals
- Drug type
- Genetic medicine
- Administration
- Subcutaneous injection
- Target protein
- Tau
- Study stage
- Early study